Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10326923 | 1.00 | CYP2D6 (0.60) | CYP2D6KDM4ENPC1CYP1A2HPGD | |
| SCHEMBL10326637 | 1.00 | CYP2D6 (0.60) | CYP2D6KDM4ENPC1CYP1A2HPGD | |
| SCHEMBL10326345 | 0.84 | KDM4E (0.47) | CYP2D6KDM4ENPC1CYP1A2HPGD | |
| SCHEMBL10326303 | 0.78 | CYP2D6 (0.59) | CYP2D6KDM4ENPC1CYP1A2HPGD | |
| SCHEMBL6441061 | 0.78 | CYP2D6 (0.59) | CYP2D6KDM4ENPC1CYP1A2HPGD | |
| SCHEMBL10327031 | 0.78 | CYP2D6 (0.59) | CYP2D6KDM4ENPC1CYP1A2HPGD | |
| SCHEMBL10326454 | 0.78 | NPC1 (0.79) | CYP2D6KDM4ENPC1CYP1A2HPGD | |
| SCHEMBL10326626 | 0.78 | NPC1 (0.79) | CYP2D6KDM4ENPC1CYP1A2HPGD | |
| SCHEMBL10326848 | 0.78 | NPC1 (0.79) | CYP2D6KDM4ENPC1CYP1A2HPGD | |
| SCHEMBL100361 | 0.77 | CYP2D6 (0.96) | CYP2D6KDM4ENPC1CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
| US-6919456-B2 | Catalytic compositions and methods for asymmetric aldol reactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1409122-A2 | CATALYTIC COMPOSITIONS AND METHODS FOR ASYMMETRIC ALDOL REACTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20040019239-A1 | Catalytic compositions and methods for asymmetric aldol reactions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| US-6610889-B2 | Using organometallic complex catalyst | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2003-08-26 | — | — | US | disclosed |
| US-20020147367-A1 | Catalytic compositions and methods for asymmetric aldol reactions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-10-10 | — | — | US | disclosed |
| WO-2002041984-A2 | CATALYTIC COMPOSITIONS AND METHODS FOR ASYMMETRIC ALDOL REACTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | CYP2D6 1125/4885KDM4E 4195/4885NPC1 2005/4885 |
| US-20020147367-A1 | Catalytic compositions and methods for asymmetric aldol reactions | ADH1C, ADH5, ADH1A | CYP2D6 235/4885KDM4E 3834/4885NPC1 1460/4885 |
| US-20040019239-A1 | Catalytic compositions and methods for asymmetric aldol reactions | ADH1C, ADH5, ADH1A | CYP2D6 235/4885KDM4E 3834/4885NPC1 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.